Compare BridgeBio Pharma Inc (BBIO) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Intuitive Surgical, Inc. — how do they compare? BridgeBio Pharma Inc trades at $84.71 (market cap $16.46B), while Intuitive Surgical, Inc. trades at $382.28 (market cap $134.40B). The key difference: Intuitive Surgical, Inc. is far larger — about 8.2× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| BBIO | ISRG | |
|---|---|---|
Market Cap | $16.46B | $134.40B |
Sector | Health | Health |
52-Week High | $90.17 | $592.85 |
52-Week Low | $44.81 | $379.50 |
Enterprise Value | $18.02B | $129.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Intuitive Surgical (ISRG) trades at $407.12, showing minimal daily change. The stock is in a bearish technical trend but maintains strong fundamentals with consistent revenue growth, expanding profit margins, and a history of earnings beats. Recent news highlights near-term headwinds and a significant decline from 52-week highs, yet analyst sentiment remains largely positive, focusing on long-term robotic surgery market penetration.
The outlook balances strong fundamentals against technical weakness. Investment opportunity lies in market leadership and earnings growth potential, but risks include competitive pressures and execution challenges. Wall Street consensus is bullish with a $557.60 price target, suggesting substantial upside if the company navigates current challenges successfully.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
